Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Chlorpheniramine cost?
Prolia and osteonecrosis?
What is dabrafenib mesylate msn patent issue?
When is tenofovir alafenamide patent expiring?
Dabrafenib mesylate when the patent is expiring in india?

What+is+jynarque?

See the DrugPatentWatch profile for jynarque

Jynarque (generic name bulevirtide) is a first‑in‑class antiviral medication approved for the treatment of chronic hepatitis B (CHB) in adults. It works by blocking the sodium‑taurocholate cotransporting polypeptide (NTCP) receptor on liver cells, which the hepatitis B virus (HBV) uses to enter hepatocytes. By inhibiting this entry step, Jynarque reduces viral replication and helps prevent progression of liver disease.

Feature Details
Drug class Viral entry inhibitor (peptide‑based)
Indication Adults with CHB who have:
• Cirrhosis,
• Elevated alanine aminotransferase (ALT) levels, or
• HBV DNA > 20 IU/mL after a prior course of nucleos(t)ide analogues (e.g., entecavir or tenofovir).
Administration Subcutaneous injection (usually 2 mg once daily, but dosing schedules may vary by country).
Mechanism of action Bulevirtide binds to the NTCP receptor, blocking HBV from attaching and entering hepatocytes, thereby halting new rounds of infection.
Efficacy Clinical trials (e.g., REACH‑B and REACH‑C) showed significant reductions in HBV DNA levels and improvements in liver function tests compared with placebo.
Common side effects Injection‑site reactions (pain, redness, swelling), nausea, headache, and mild fatigue.
Contraindications/Warnings Not recommended in patients with severe hepatic impairment, significant renal dysfunction, or hypersensitivity to the drug.
Drug interactions Limited data; avoid concomitant use with medications that heavily rely on hepatic transporters.
Monitoring Routine liver function tests, HBV DNA quantification, and renal function assessments are advised during therapy.

How it fits into CHB management

  • Complementary therapy: Jynarque is usually used in patients who have not responded adequately to or cannot tolerate standard nucleos(t)ide analogues.
  • Potential advantage: Because it targets viral entry rather than replication alone, it may help achieve deeper viral suppression in difficult‑to‑treat patients.

Key points to remember

  1. Not a cure – Jynarque reduces viral load but does not eradicate HBV; ongoing therapy may be required.
  2. Adjunctive – Often combined with or followed by nucleos(t)ide analogues to maintain suppression.
  3. Availability – Approved in the EU, UK, and several other regions; availability may vary by country.

Bottom line
Jynarque is a novel, subcutaneous antiviral that blocks the cellular entry of hepatitis B virus. It offers a new therapeutic option for adults with chronic hepatitis B, especially those with advanced disease or who have limited response to existing treatments. If you’re considering this medication, discuss it with a hepatologist or infectious‑disease specialist to understand whether it’s appropriate for your specific situation.



Other Questions About Jynarque :

jynarque+price Jynarque generic? Jynarque mechanism of action? Buy jynarque? Jynarque price? Jynarque generic availability? Jynarque used for?